| Objective:The relationship between specific Ig G4 in saliva and the patient's symptoms was studied through the use of specific immunotherapy and drug therapy in patients with allergic rhinitis,4 months after treatment,1 year after treatment,and serum and salivary house dust mite Ig G4.Study the changes of Ig G4,the main allergen of house dust mite in saliva;Study the change of specific Ig G4 in saliva in the course of specific immunotherapy;Study the correlation of allergen Ig G4 in saliva and serum;Thus study saliva The possibility of allergen-specific Ig G4 as a biological parameter for efficacy in immunotherapy.Methods:48 perennial AR patients who were diagnosed in the allergy department of the Second People's Hospital of Wuhu City were randomly divided into immunotherapy group(30 cases)and drug treatment group(18 cases).For the patients with allergic rhinitis,4 months after the specific immunotherapy,the symptoms were scored 1 year after treatment,and serum Ig G4 and salivary house dust mite Ig G4 were detected.Results: After 4 months of treatment,the symptom score(4.0 [2.0,7.0])and the drug score(1 [0,2])in immunotherapy group were significantly lower than those before treatment(8.0 [6,10],8.0 [6,10])were significantly decreased and the difference was statistically significant(z values were-4.609,-3.054,P values were <0.05),and the drug treatment group(7 [6.0,10.5] Points,3 [1.75,3] points)compared with the difference was statistically significant(u values were 114,117,P values were <0.05).After 4months of treatment,the immunoglobulin Ig G4 level of house dust mites in the immunotherapy group was significantly higher(9644.8 [3001.35,19537.15(AU / ml) vs 504.75 [213.18,1031.8](AU/ml)The difference was statistically significant(u value9.0 and P<0.05 respectively)(P <0.05).The difference was significant(P <0.05)with the drug treatment group Ig G4 435.9 [300.28,1134.38] AU / 0.05).After 4 months of treatment,the Ig G4 of salivary house dust mite in immunotherapy group was 2.66[0.37,8.12] AU / ml,which was significantly higher than 0.075 [0,0.73](AU / ml)before treatment and the difference was statistically significant(Z value-4.458,P<0.05).The difference was also statistically significant compared with Ig G4 0.075 [0,0.33] AU /ml of salivary house dust mites in medical treatment group(u values were 110.0,P values were < 0.05).After 4 months of treatment,the symptom scores of patients in immunotherapy group were negatively correlated with the changes of Ig G4 in house dust mite(r =-0.63,P = 0.00).The symptom scores of patients in immunotherapy group were significantly lower than those in house sputum Ig G4 was negatively correlated(r =-0.588,P = 0.001).There was a positive correlation between the changes of Ig G4 in house-keeping house dust mite and the Ig G4 of house-dust mite in the immunotherapy group(r = 0.893,P = 0.00).After 1 year of treatment,the symptom scores(2 [1,4] points)in immunotherapy group were significantly lower than those before treatment(6 [4,10]points)and the difference was statistically significant(z value-2.949 b,P <0.05).The difference was statistically significant(u value 40,P <0.05)compared with the drug treatment group(6 [4,8]).After one year of treatment,the immunoglobulin Ig G4 level of12 1099.7 [5872.4,28936.4] AU / ml in immunotherapy group was significantly higher than 378.5 [125.8,985.8] AU / ml before treatment and the difference was statistically significant(z Value-4.78,P <0.05).The difference was statistically significant(u = 0.00,P <0.05,respectively)as compared with Ig G4 445.9 [307.63,1115.5] AU / ml in the drug treatment group.After one year of treatment,the immunoglobulin Ig G4 in the salivary house dust mite immunized group was 4.57 [2.34,16.8] AU / ml,which was significantly higher than 0 [0,1.46] AU / ml before treatment and the difference was statistically significant(z-2.934,P <0.05).The difference was also statistically significant compared with the Ig G4 0.07 [0,0.33] AU / ml of salivary house dust mite medication group(u values were 18,P <0.05).After one year of treatment,the symptom scores of patients in immunotherapy group were negatively correlated with the changes of Ig G4 in house dust mite(r =-0.535,P = 0.09)(R =-0.647,P = 0.032).There was a positive correlation between the changes of Ig G4 in the house dust mites and the changes of Ig G4 in the house dust mites in the immunotherapy group(r = 0.893,P =0.002).Conclusion:Specific immunotherapy can significantly improve the patient's allergy symptoms.Alteration of symptomatic scores after specific immunotherapy in patients with allergic diseases was negatively correlated with changes in Ig G4 in house dust mites.Symptom changes in patients with allergic disease after immunotherapy were negatively correlated with changes in Ig G4 in house dust mites.The allergen-specific Ig G4 in saliva of patients with allergic diseases gradually increased during the specific immunotherapy.The changes of Ig G4 in house dust mites were positively correlated with the changes of Ig G4 in house dust mites of salivary glands,suggesting that allergen-specific Ig G4 As a biological parameter of therapeutic efficacy during immunotherapy. |
PDF Full Text Request